Cell Reports · 2019 · 52 citations · 46 references
Life SciencesInfectious DiseasesMicrobiologyDrug DesignHost-pathogen InteractionsMicrobial PathogenesisBacterial PathogenesisFatty Acid BiosynthesisFatty Acid ChemistryFatty Acid SynthesisSepsis PathophysiologyTargeted Antimicrobial TherapyAcyl Carrier Protein FunctionBacterial Fatty Acid BiosynthesisBacterial Membrane Lipid CompositionGrowth In Host EnvironmentsMembrane Fatty Acid CompositionMembrane Stability Under StressMembrane Stress ResponseResistance Mechanisms In Staphylococci
The essentiality of fatty acid synthesis (FASII) products in the human pathogen Staphylococcus aureus is the underlying rationale for FASII-targeted antimicrobial drug design. Reports of anti-FASII efficacy in animals support this choice. However, restricted test conditions used previously led us to investigate this postulate in a broader, host-relevant context. We report that S. aureus rapidly adapts to FASII antibiotics without FASII mutations when exposed to host environments. FASII antibiotic administration upon signs of infection, rather than just after inoculation as commonly practiced, fails to eliminate S. aureus in a septicemia model. In vitro, serum lowers S. aureus membrane stress, leading to a greater retention of the substrates required for environmental fatty acid (eFA) utilization: eFAs and the acyl carrier protein. In this condition, eFA occupies both phospholipid positions, regardless of anti-FASII selection. Our results identify S. aureus membrane plasticity in host environments as a main limitation for using FASII antibiotics in monotherapeutic treatments.
46
Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
Sophie M. Lehar, Thomas H. Pillow, Min Xu et al. · Nature · 2015 · 833 citations